Cognition Therapeutics secures FDA alignment on pivotal Phase 3 trial of zervimesine for dementia with Lewy bodies
Cognition Therapeutics announced that the U.S. Food and Drug Administration has agreed on the design of a registrational Phase 3 study for its oral drug zervimesine (CT1812) in patients with mild‑to‑moderate dementia with Lewy bodies. The trial will randomize participants to 100 mg daily of zervimesine or placebo for nine months, using a neuropsychiatric inventory that measures hallucinations and delusions as the primary endpoint and a functional activities scale as a key secondary endpoint. The company highlighted that there are currently no approved therapies for this condition, which affects an estimated 1.4 million Americans.
Why it matters
The FDA alignment clears a regulatory hurdle, allowing Cognition to move forward with a registrational trial that could become the first approved treatment for DLB. Successful results could significantly expand the company’s market opportunity and drive its stock price, as noted by the pre‑market price increase reported in material 5.
Key facts
- 1The FDA and Cognition agreed on patient selection, dose (100 mg once‑daily), study duration (nine months) and clinical endpoints for the Phase 3 DLB trial. stocktitan.net
- 2The trial will enroll patients with mild‑to‑moderate dementia with Lewy bodies. stocktitan.net
- 3The primary endpoint will be the Neuropsychiatric Inventory (NPI‑2) measuring hallucinations and delusions. stocktitan.net
- 4A key secondary endpoint will assess daily functional ability using the Alzheimer's Disease Cooperative Study – Activities of Daily Living scale. stocktitan.net
- 5Dementia with Lewy bodies affects an estimated 1.4 million Americans. stocktitan.net
- 6CGTX closed at $0.74, up 1.74%, and was up 7.02% in pre‑market trading after the announcement. rttnews.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.